Literature DB >> 20171708

Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging.

Sathya Prakash Manimunda1, Paluru Vijayachari, Raghuraj Uppoor, Attayur Purushottaman Sugunan, Shiv Shankar Singh, Subhodh Kumar Rai, Anakkathil Balan Sudeep, Nagarajan Muruganandam, Itta Krishna Chaitanya, Dev Reddy Guruprasad.   

Abstract

This longitudinal follow-up study of 203 patients with serologically confirmed chikungunya (CHIK) virus infection describes the clinical features of CHIK fever during the first and tenth months of illness. During the acute stage CHIK fever presents with a wide array of symptoms. The foremost chronic symptoms at the end of a month were rheumatism (75%) and fatigue (30%). During the tenth month of follow-up the symptoms/signs observed were joint pain/swelling (46%), fatigue (13%) and neuritis (6%). The cure rate at the end of 9 months was 51%. Among the patients who had joint pain, 36% (34/94) met the American College of Rheumatology criteria to classify them as having rheumatoid arthritis. A subpopulation of the patients with joint pain (20/94) was tested for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody, and the joints were imaged by X-ray and magnetic resonance imaging (MRI). All tested negative for RF and one tested positive for anti-CCP. A radiolucent lesion in the X-ray was seen in the bones of five patients. The MRI findings were joint effusion, bony erosion, marrow oedema, synovial thickening, tendinitis and tenosynovitis. The study proves with relative certainty that CHIK arthritis is chronic inflammatory erosive arthritis, which has implications for management of the infection. 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20171708     DOI: 10.1016/j.trstmh.2010.01.011

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  69 in total

1.  Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis.

Authors:  Jonathan J Miner; Lindsey E Cook; Jun P Hong; Amber M Smith; Justin M Richner; Raeann M Shimak; Alissa R Young; Kristen Monte; Subhajit Poddar; James E Crowe; Deborah J Lenschow; Michael S Diamond
Journal:  Sci Transl Med       Date:  2017-02-01       Impact factor: 17.956

2.  How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

Authors:  A J Rodriguez-Morales; J A Cardona-Ospina; W Villamil-Gómez; A E Paniz-Mondolfi
Journal:  Rheumatol Int       Date:  2015-06-05       Impact factor: 2.631

Review 3.  Curious entanglements: interactions between mosquitoes, their microbiota, and arboviruses.

Authors:  Eric P Caragata; Chinmay V Tikhe; George Dimopoulos
Journal:  Curr Opin Virol       Date:  2019-06-05       Impact factor: 7.090

Review 4.  Chronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common.

Authors:  J Kennedy Amaral; Joshua B Bilsborrow; Robert T Schoen
Journal:  Am J Med       Date:  2019-11-06       Impact factor: 4.965

5.  Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues.

Authors:  Bennett J Davenport; Christopher Bullock; Mary K McCarthy; David W Hawman; Kenneth M Murphy; Ross M Kedl; Michael S Diamond; Thomas E Morrison
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

6.  Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection.

Authors:  Mariangelí Arroyo-Ávila; Amanda Cabán; Enid J García-Rivera; Marisela Irizarry-Pérez; Hilda Torres; Héctor Gorbea; Luis M Vilá
Journal:  Am J Trop Med Hyg       Date:  2017-01-30       Impact factor: 2.345

7.  Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study.

Authors:  Vinod Ravindran; George Alias
Journal:  Clin Rheumatol       Date:  2016-10-04       Impact factor: 2.980

8.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

9.  Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice.

Authors:  Kristin M Long; Alan C Whitmore; Martin T Ferris; Gregory D Sempowski; Charles McGee; Bianca Trollinger; Bronwyn Gunn; Mark T Heise
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

Review 10.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.